The new BTX 1702 program is being expedited based on the recent Phase 2 acne study data andmechanistic data recently generated by Botanix that showed synthetic cannabidiol exerts powerfulanti-inflammatory and antimicrobial actions in skin – two key activities that are critical to successfullytreating rosacea
Ann: Botanix Initiates BTX 1702 Rosacea Study, page-5
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $563.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 33.0¢ | 31.0¢ | $1.731M | 5.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 606129 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 92444 | 5 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |